Moneyta · stock research · no sign-up needed
LLY
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue (Q2 FY2026)
$23.0B
+80.5% y/y
Net income (Q2 FY2026)
$7.1B
as filed with the SEC
Institutions holding
4,645
+256 last quarter
Overview · Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta f…
Management team
- Mr. Gordon Brooks · Group VP, Controller & Corporate StrategyFind on LinkedIn
- Mr. Jacob S. Van Naarden · Executive VP & President of LoxoFind on LinkedIn
- Ms. Anat Hakim J.D. · Executive VP, General Counsel & SecretaryFind on LinkedIn
- Dr. Daniel M. Skovronsky M.D., Ph.D. · EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunologyFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on LLY
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.